Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KDM6B | O15054 | 1/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10370235 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4EGAAMAPTTDP1 | |
| SCHEMBL1643711 | 0.80 | KDM4C (0.73) | ALDH1A1KDM4EGLAGAAMAPT | |
| SCHEMBL2515356 | 0.79 | SMN1; SMN2 (0.52) | ALDH1A1GAAMAPTMEN1KMT2A | |
| SCHEMBL322168 | 0.79 | CTSD (0.62) | LMNAALOX15HSD17B10CTSDCNR2 | |
| SCHEMBL29658169 | 0.79 | CTSD (0.62) | LMNAALOX15HSD17B10CTSDCNR2 | |
| SCHEMBL1643574 | 0.77 | RECQL (0.55) | ALDH1A1KDM4EGLAGAAMAPT | |
| SCHEMBL27789892 | 0.77 | CTSD (0.60) | LMNAALOX15HSD17B10CTSDCNR2 | |
| SCHEMBL30570841 | 0.76 | TSHR (0.64) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL3818697 | 0.76 | KDM4E (0.59) | ALDH1A1KDM4EMEN1KMT2ATDP1 | |
| SCHEMBL9270162 | 0.76 | TSHR (0.64) | ALDH1A1KDM4EMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098298-A1 | New Pyridin-3-Amine Derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2011-04-28 | — | — | US | disclosed |
| US-7906530-B2 | 1,7-naphthyridine derivatives as p38 MAP kinase inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2011-03-15 | — | — | US | disclosed |
| US-20100227881-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-09-09 | — | — | US | disclosed |
| EP-1987005-A2 | NEW PYRIDIN-3-AMINE DERIVATIVES | Laboratorios Almirall, S.A. (ES) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007096072-A2 | NEW PYRIDIN-3-AMINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098298-A1 | New Pyridin-3-Amine Derivatives | MAPK1, MAP4K2, MAPK3 | ALDH1A1 3124/4885KDM4E 2470/4885GLA 4310/4885 |
| US-20100227881-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | MAPK1, MAPK7, MAPKAPK2 | ALDH1A1 2099/4885KDM4E 4589/4885GLA 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.